No Detail Found!

Efficacy of Shuganjieyu capsule for treatment of neurologic disorders combined with depression: A meta-analysis

Author(s)
Xiao Huang Department of Psychological Medicine, Zhongshan Hospital,Fudan Univeristy, Shanghai,China
Tian Song Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; Department of Neuropsychiatry and Behavior Neurology and Clinical Psychology Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; China National Clinical Research Center for Neurological Diseases, Beijing, China; Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
Zhou Ding Beijing Hospital of Integrated Traditional Chinese and Western Medicine,Beijing,China
Delin Wang Shenyang Mental Health Center,Shenyang,China
Chunxue Wang Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; Department of Neuropsychiatry and Behavior Neurology and Clinical Psychology Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; China National Clinical Research Center for Neurological Diseases, Beijing, China; Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China
Abstract
Shuganjieyu capsule (SGJY) is the first Chinese herbal medicine approved for treatment of depression; however, the Shuganjieyu capsule efficacy in patients with neurologic disorders combined with depression remains to be determined. Embase, PubMed, Cochrane Library, China National Knowledge Infrastructure (CNKI) and other electronic databases were searched to obtain relevant studies through May 2019. Newcastle-Ottawa and Jadad scales are used for the quality assessed. Sensitivity analysis, subgroup analysis and meta-regression were performed to evaluate sources of heterogeneity. Sixty-seven studies were selected for further analysis. Patients who had Shuganjieyu therapy had a higher effective rate and lower Hamilton Depression Rating Scale (HAM-D) score compared to patients who had nonshuganjieyu therapy. In addition, Shuganjieyu capsule improve symptoms of patients with stroke (National Institutes of Health Stroke Scale (NIHSS) score: Weighted mean difference (WMD)= -2.64; 95% CI: -3.95 to -1.33; P<0.001), Parkinson's disease score: WMD= -2.53; 95% CI: -3.92 to -1.14; P<0.001), and sleep disorders (Pittsburgh Sleep Quality Index (PSQI) score: WMD= -4.97; 95% CI: -7.56 to -2.38; P<0.001). Our results demonstrated that there were clinical benefits for patients with neurologic disorders after Shuganjieyu capsule therapy compared with non-shuganjieyu therapy with respect to effective rate and HAM-D, NIHSS, UPDRS and PSQI scores.
Publication Details
Page(s) 1445-1458
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 35, Issue: 5, Year: 2022

Request the full text from PASTIC

Keywords
Stroke, Depression, Shuganjieyu capsule, Parkinson's disorder., neurologic disorders
0

Citations

0

Downloads

67

Views